Lewis and Clark Pharmaceuticals is a Charlottesville, Va.-based developer of novel adenosine-based pharmaceutical compounds targeting autoimmune diseases and stress imaging. Led by Founder and CEO Robert Thompson, Ph.D., the company initially focuses on autoimmune indications such as rheumatoid arthritis and on stress imaging markets. Its core product work centers on adenosine-based compounds intended for therapeutic and diagnostic applications. The company raised $100K from the Center for Innovative Technology (CIT) via the GAP Funds to continue advancing its compounds. Lewis and Clark intends to use the capital to further develop its pipeline. No operating metrics or prior financings are disclosed in the article.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2012